Edgar Filing: BIOMARIN PHARMACEUTICAL INC

Ownership Submission

FORM 4

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:

3235-0287

Expires:

January 31, 2005

Estimated average burden hours per response...

0.5

(Print or Type Responses)

1. Name and Address of Reporting Person ^*

BIENAIME JEAN JACQUES

2. Issuer Name and Ticker or Trading Symbol
BIOMARIN PHARMACEUTICAL INC [BMRN]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

__X__ Director	_____ 10% Owner
__X__ Officer (give title below)	_____ Other (specify below)
Chief Executive Officer

(Last)

(First)

(Middle)

C/O BIOMARIN PHARMACEUTICAL INC., 770 LINDARO ST.

3. Date of Earliest Transaction (Month/Day/Year)
03/03/2015

(Street)

SAN RAFAEL, CA 94901

4. If Amendment, Date Original Filed(Month/Day/Year)

6. Individual or Joint/Group Filing(Check Applicable Line)
_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

(City)

(State)

(Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	03/03/2015	03/03/2015	A		39,600	A	$ 0 ⁽¹⁾	254,757	D
Common Stock	03/05/2015	03/05/2015	M		10,000	A	$ 12.99	52,279	I	Shares held by Bienaime Family Trust ⁽²⁾
Common Stock	03/05/2015	03/05/2015	S		10,000	D	$ 113.7016 ⁽³⁾	42,279	I	Shares held by Bienaime Family Trust ⁽²⁾

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
	Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.		SEC 1474 (9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security
(Instr. 3)

2. Conversion or Exercise Price of Derivative Security

3. Transaction Date (Month/Day/Year)

3A. Deemed Execution Date, if any (Month/Day/Year)

4. Transaction Code
(Instr. 8)

5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4, and 5)

6. Date Exercisable and Expiration Date
(Month/Day/Year)

7. Title and Amount of Underlying Securities
(Instr. 3 and 4)

8. Price of Derivative Security
(Instr. 5)

9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 4)

10. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 4)

11. Nature of Indirect Beneficial Ownership
(Instr. 4)

Code

(A)

(D)

Date Exercisable

Expiration Date

Title

Amount or Number of Shares

Stock Option (right to buy) Common Stock

$ 108.36

03/03/2015

90,500

09/03/2015⁽⁴⁾

03/02/2025

Common Stock

90,500

$ 0

90,500

Stock Option (right to buy Common Stock)

$ 12.99

03/05/2015

10,000

11/11/2006⁽⁵⁾

05/10/2016

Common Stock

10,000

$ 0

51,500

Shares held by Bienaime Family Trust

Stock Option (right to buy Common Stock)

$ 12.99

11/11/2006⁽⁵⁾

05/10/2016

Common Stock

10,000

Held in irrevocable trust for Guillaume Bienaime ⁽⁶⁾

Stock Option (right to buy Common Stock)

$ 12.99

11/11/2006⁽⁵⁾

05/10/2016

Common Stock

10,000

Held in irrevocable trust for Pierre Bienaime ⁽⁶⁾

Stock Option (right to buy Common Stock)

$ 12.99

11/11/2006⁽⁵⁾

05/10/2016

Common Stock

10,000

Held in irrevocable trust for Paul Bienaime ⁽⁶⁾

Stock Option (right to buy Common Stock)

$ 12.99

11/11/2006⁽⁵⁾

05/10/2016

Common Stock

10,000

Held in irrevocable trust for Marc Bienaime ⁽⁶⁾

Stock Option (right to buy Common Stock)

$ 12.99

11/11/2006⁽⁵⁾

05/10/2016

Common Stock

20,000

Held in irrevocable trust for Aurelie Mitsuki Bienaime & Anais Kimiko Bienaime ⁽⁶⁾

Reporting Owners

Reporting Owner Name / Address	Relationships
Reporting Owner Name / Address	Director	10% Owner	Officer	Other
BIENAIME JEAN JACQUES C/O BIOMARIN PHARMACEUTICAL INC. 770 LINDARO ST. SAN RAFAEL, CA 94901	X		Chief Executive Officer

Signatures

/s/ Laura Randall Woodhead, Attorney-in-Fact		03/05/2015
^**Signature of Reporting Person		Date

Explanation of Responses:

*	If the form is filed by more than one reporting person, see Instruction 4(b)(v).
**	Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
(1)	Restricted stock units granted on March 3, 2015. Price not applicable.
(2)	The reporting person an his spouse act as trustees for the Bienaime Family Trust
(3)	The price in column 4 is an average weighted price. The price actually received ranged from $113.27 to $114.00. The issuing person shall provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the amount of shares sold at each price within the range.
(4)	Option grant vests 6/48ths on September 3, 2015, and 1/48th on the 3rd day of every month thereafter
(5)	Original option grant vests 6/48ths on November 11, 2006, and 1/48th on the 11th of every month thereafter.
(6)	The reporting person's spouse is the trustee of each child's trust.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.